ICON plc

ICON plc is an Irish-headquartered multinational clinical research organization (CRO) that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, the company's mission is to accelerate the development of drugs and devices that save lives and improve the quality of life. Its corporate headquarters are located in Dublin, Ireland.

ICON offers a comprehensive range of services spanning the entire product lifecycle, from early-phase clinical trials to post-market surveillance and commercialization. These services include clinical trial management, consulting, laboratory services, strategic solutions, language services, medical imaging, and real-world intelligence. The company serves various market segments, including pharmaceutical, biotechnology, medical device, government, and public health organizations, with expertise across numerous therapeutic areas such as oncology, cardiovascular, infectious disease, and immunology. ICON leverages advanced technological platforms, including AI for trial design and site selection, to enhance efficiency and outcomes.

As of December 2025, ICON plc operates in over 55 countries with approximately 40,100 employees, positioning itself as one of the world's leading and top three global CROs, a standing solidified by its $12 billion acquisition of PRA Health Sciences in 2021. Barry Balfe serves as the Chief Executive Officer, appointed in October 2025. Recent notable developments include the completion of an internal accounting investigation in April 2026, which revealed a minor revenue overstatement for 2023 and 2024, leading to a stock rebound. The company also reported strong Q1 2026 performance and selected Microsoft as a preferred technology partner for AI-enabled clinical development.